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Abstract: Organ clearance, which has been derived from the organ blood flow and extraction 
ratio (E), has been extensively used by clinical pharmacologists to explain the pharmacokinetics 
of many drugs in health and disease. For example, the extent of hepatic clearance or E (Eh) of 
drugs would determine their response to changes in the liver blood flow and/or activities of the 
metabolizing enzymes. Although Eh may be obtained directly by cannulating internal blood 
vessels, the method is invasive. Therefore, indirect methods have been used to estimate Eh from 
the peripheral blood concentration-time data after intravascular administration of drugs. 
Additionally, these indirect methods require an estimate of the liver blood flow in the patients or 
animals. However, some investigators use plasma concentrations and/or liver plasma flow for 
the estimation of Eh, which could potentially result in significant errors. It is shown here that 
when plasma concentrations are used along with liver blood flow, an overestimation or 
underestimation of the true value will result if the blood: plasma concentration (B:P) ratio is >1 
or < 1, respectively, with the estimated Eh being different from the true value by a factor equal to 
the B:P ratio. On the other hand, the use of plasma concentrations and plasma liver flow will 
always result in an overestimation of the true Eh unless the drug does not penetrate the red blood 
cells. It is concluded that for the accurate estimation of Eh from the in vivo data, the blood 
concentration and blood flow should be used.  
Key Words: Systemic clearance, organ clearance, hepatic clearance, renal clearance, hepatic 
extraction ratio, hepatic availability, liver blood flow, blood: plasma ratio.   
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INTRODUCTION AND THEORETICAL BACKGROUND 
The two major organs of elimination are kidneys (excretion of unchanged drugs and/or 
their metabolites) and liver (metabolism and biliary excretion of drug). There are some drugs, 
which are almost entirely eliminated by either renal excretion of the parent drug (such as 
atenolol) or by hepatic metabolism only (such as propranolol) [1]. However, most drugs are 
eliminated by a combination of both pathways. For example, 60% of digoxin or 70% of 
procainamide is excreted unchanged in urine, while the remainder is metabolized by the liver [1]. 
The clearance (Cl) value obtained from the blood concentration-time data, which is sometimes 
called total or systemic clearance, is a summation of the individual organ clearance values 
contributing to the overall elimination of the drug as demonstrated in Equation (1): 
Cl = Clr + Clh + Clo (1) 
where Clr, Clh, and Clo refer to the renal, hepatic, and other organ clearances, respectively. 
Among the clearance terms in Equation (1), only Cl and Clr could be directly estimated using the 
following equations: 𝐶𝑙 = !"#$!"#!!! (2) 𝐶𝑙! = !!!!"#!!! (3) 
where AUC0-∞ and 𝐴!! are the area under the blood concentration-time curve and the amount of 
drug excreted unchanged into the urine from time zero to infinity, respectively. In contrast to Cl 
and Clr, Clh cannot be directly quantified in most cases. Additionally, Clo is unknown for most 
drugs. Therefore, in most literature, Clh and Clo are lumped together and presented as non-renal 
clearance (Clnr): 
Cl = Clr + Clnr (4) 
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The concept that the systemic (total) clearance is a summation of the individual organ clearances 
is called clearance additivity and is a useful concept for the estimation of Clnr or Clh indirectly 
once the Cl and Clr values are estimated directly: 𝐶𝑙!" 𝑜𝑟  𝐶𝑙! = 𝐶𝑙 − 𝐶𝑙! (5) 
The concept of clearance additivity is only true when organs of elimination receive their blood 
supplies in parallel, such as kidneys and the liver. However, when the organs of elimination 
receive their blood supplies in series, such as pulmonary clearance in relationship to renal and/or 
hepatic clearance, the equations describing the relationship between the total and organ 
clearances are much more complex [2].   
Loss of Drug Across an Organ of Elimination: Extraction Ratio 
 Figure (1) depicts the events that occur during the passage of a drug through an 
eliminating organ, such as the liver. As demonstrated, the drug enters the organ via the organ 
blood flow of Q and an inlet drug concentration of Cin. If the drug is extracted by the organ as the 
blood travels through it, the concentration of the drug in the blood leaving the organ (Cout) would 
be less than Cin. The fraction of the drug that is extracted by the liver (converted to metabolites 
and/or excreted into the bile) during one passage through the liver is called hepatic extraction 
ratio (Eh). In practice, one normally cannot directly measure what is extracted. However, Eh may 
be obtained from the differences in the Cin and Cout using the following equation: 
𝐸! = !!"!!!"#!!"  (6) 
In contrast to Eh, hepatic availability (Fh) is the fraction of the drug that escapes metabolism in 
the liver and is defined by Equation (7): 
𝐹! = 1− 𝐸! (7) 
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If we consider the liver as the organ of elimination, some drugs may not be eliminated (or 
extracted) by the liver. For these drugs, hepatic E is zero (such as drugs that are entirely 
eliminated by renal excretion). At the other extreme, almost all drug molecules present in the 
inlet blood may be extracted in one passage through the liver. For these drugs, the hepatic E is 
close to 1. Although a number of drugs (such as propranolol, lidocaine and propoxyphene) have 
high E, there is no such a drug with an absolute Eh of 1. Additionally, Eh should not be confused 
with the fraction of the drug metabolized by the liver (fm). These are two entirely different 
parameters. For instance, a drug may be eliminated by metabolism only (fraction metabolized of 
1), but its Eh may be very low. This means that the drug is metabolized slowly, but eventually all 
drug is eliminated by this route. Examples of such drugs are warfarin and tolbutamide with Eh 
values of  ≤ 0.01.     
Loss of Drug Across an Organ of Elimination: Organ Clearance 
One of the definitions of clearance is the volume of blood cleared of drug per unit of time. 
For hepatic clearance (Clh), it is the volume of blood perfusing the liver (Qh), which is cleared of 
drug per unit of time. Combining this definition with the definition of Eh, which is the fraction of 
the drug that is extracted by the liver during one passage, it is clear that organ clearance (in this 
case Clh) is defined by the following equation:  𝐶𝑙! = 𝑄! ∙ 𝐸! (8) 
Based on the above discussion, the minimum and maximum values possible for hepatic clearance 
of drugs are zero (no hepatic extraction) and Qh (Eh of 1). 
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ESTIMATION OF IN VIVO HEPATIC EXTRACTION RATIO OF DRUGS 
One of the most widely used applications of organ clearance in pharmacokinetics 
research is the estimation the hepatic E of drugs in humans or animals. Estimation of Eh of drugs 
is important because it would allow prediction of the drug behavior when the physiologic 
determinants of Eh or Clh are altered as a result of disease states, age, or drug-drug interactions. 
Direct Estimation of Eh  
Direct estimation of Eh requires invasive surgical procedures to insert catheters in 
multiple blood vessels, which also requires laparotomy.  For example, Burns et al. [3] 
determined the Eh of indocyanine green in rats by cannulating and obtaining blood samples from 
the carotid artery and hepatic vein after intravenous infusion of the marker. They then used 
Equation (6), substituting carotid artery and hepatic vein concentrations of indocyanine green for 
Cin and Cout, respectively, to estimate Eh. 
In a less direct experimental design, Ward et al. [4, 5] cannulated the portal and femoral 
veins of monkeys and estimated the Eh of a number of drugs after their intraduodenal bolus 
administration using the following equation:  𝐸! = !"#!"!!"#!!"#!"  (9) 
where AUCpv and AUCs are the portal vein and systemic (femoral vein) AUC of the drug, 
respectively. However, Equation (9) is valid only when the elimination of the drug is primarily 
through the liver, following linear pharmacokinetic principles.   
In a similar procedure, Kanazu et al. [6] cannulated the jugular (systemic) and portal 
veins of rats and determined the hepatic availability (Fh) of midazolam after the oral and 
intravenous administration of the drug using Equation (10): 
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𝐹! = !"#!",!"!#$%&'!"#!",!"!#$%&' × !"#!",!"#$%&!"#!",!"#$%&  (10) 
where 𝐴𝑈𝐶!",!"!#$%&'  and 𝐴𝑈𝐶!",!"!#$%&'  are the systemic (jugular vein) AUCs and 𝐴𝑈𝐶!",!"#$%&     and 𝐴𝑈𝐶!",!"#$%&  are the portal AUCs after the oral and intravenous dosing, 
respectively. An estimate of Eh is then obtained using Equation (7). In contrast to Equation (9), 
estimation of Eh via Equation (10) does not require an assumption of hepatic elimination only.    
Indirect Estimation of Eh  
The Eh of drugs may be estimated indirectly from the blood concentration-time data after 
intravenous administration of drugs, without catheterization of the internal blood vessels, using a 
rearranged version of Equation (8): 𝐸! = !"!!!  (11) 
Generally, in these cases, the systemic clearance (Cl) of the drug is estimated from the 
AUC0-∞ data and the dose using Equation (2) (𝐶𝑙 = 𝐷𝑜𝑠𝑒/𝐴𝑈𝐶!!!). If the drug is almost 
completely eliminated by hepatic metabolism, it is assumed that Clh is equal to Cl, and using an 
average Qh in the animal or humans, an approximate value of Eh is estimated from Equation (11). 
However, if the drug is subject to a measurable renal clearance (Clr), Clh is first estimated by 
subtracting Clr from Cl, using Equation (5), before substituting Clh in Equation (11). At best, the 
values of Eh obtained in this manner are approximates because other organ clearances, if indeed 
exist, are not normally or easily measurable without additional experimental procedures. 
However, in the absence of any known pathways other than Clh and/or Clr, the Eh value obtained 
in this manner is normally a reasonable estimate of Eh.   
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The Use of Blood versus Plasma (or Serum) Data for Indirect Estimation of Eh 
It should be noted that the use of Equation (11) to estimate Eh requires the availability of 
blood (not plasma or serum) concentration-time data to be used with blood flow parameters. 
Therefore, the correct determination of Eh requires the use of hepatic blood clearance (𝐶𝑙!,!"##$) 
and blood flow (𝑄!,!"##$) [7]: 𝐸! = !"!,!"##$!!,!"##$  (12) 
However, there are examples in the literature where the plasma (or serum) AUC is used 
interchangeably with blood AUC [8], resulting in errors in the estimation of Eh, if the blood: 
plasma concentration (B:P) ratio is not equal to 1. In other cases, investigators have used plasma 
AUCs and have divided the plasma clearance by the hepatic plasma flow [9]. As demonstrated in 
the following sections, both of these methods (use of plasma clearance and liver blood flow or 
plasma clearance and liver plasma flow) would result in substantial errors in most cases.   
Errors in Indirect Estimation of Eh Using Hepatic Plasma Clearance and Liver Blood Flow 
(𝑬𝒉! ) 
The hepatic extraction ratio (𝐸!! ) obtained from the hepatic plasma clearance (𝐶𝑙!,!"#$%#) 
and blood flow (𝑄!,!"##$) is estimated using the following equation: 𝐸!! = !"!,!"#$%#!!,!"##$  (13) 
Dividing Equation (13) by Equation (12) would result in the following relationship: 
!!!!! = !"!,!"#$%# !!,!"##$!"!,!"##$ !!,!"##$ = !"!,!"#$%#!"!,!"##$  =!!∙!"#$ !"#!"#$%#!!∙!"#$ !"#!"##$ = !"#!"##$!"#!"!"#! = 𝐵:𝑃  𝑅𝑎𝑡𝑖𝑜 (14) 
where fm is the fraction of the dose that is eliminated by the liver and B:P ratio is the blood: 
plasma concentration ratio. Rearranging Equation (14) would result in the following relationship 
between 𝐸!!  and 𝐸!: 
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𝐸!! = 𝐸!×𝐵:𝑃  𝑅𝑎𝑡𝑖𝑜 (15) 
The relationship between 𝐸!!  and true Eh for drugs with B:P ratios of less than, equal to, or 
greater than 1 are shown in Figure (2).  As shown in Equation (15) and Fig. (2), the 𝐸!!  value is 
different from the true Eh by a factor equal to B:P ratio. Therefore, whereas the value of 𝐸!!  and 
Eh are identical when the B:P ratio is equal to 1, when B:P ratio is > or < 1, the 𝐸!!  value is 
proportionally higher or lower than Eh, respectively.  
Errors in Indirect Estimation of Eh Using Hepatic Plasma Clearance and Liver Plasma 
Flow (𝑬𝒉!!) 
The hepatic extraction ratio (𝐸!!!) obtained from the hepatic plasma clearance (𝐶𝑙!,!"#$%#) 
and plasma flow (𝑄!,!"#$%#) is estimated using the following equation: 𝐸!!! = !"!,!"#$%#!!,!"#$%#  (16) 
The hepatic plasma flow (𝑄!,!"#$%#) is a function of hepatic blood flow (𝑄!,!"##$) and 
blood hematocrit (HCT) as shown below: 𝑄!,!"#$%# = (1− 𝐻𝐶𝑇)×𝑄!,!"##$ (17) 
Substitution of Equation (17) into Equation (16) and rewriting the clearance terms in 
terms of AUC values into Equations Equation (12) for Eh and Equation (16) for 𝐸!!! would yield 
Equations (18) and (19), respectively: 𝐸! = !"!,!"##$!!,!"##$ = !!∙!"#$ !"#!"##$!!,!"##$  (18) 𝐸!!! = !"!,!"#$%#!!,!"#$%# = !!∙!"#$ !"#!"#$%#(!!!"#)×!!,!"##$  (19) 
Dividing Equation (19) by (18) would result in the following relationships: 
!!!!!! = !!∙!"#$ !"#!"#$%#(!!!"#)×!!,!"!!"!!∙!"#$ !"#!"##$!!,!"##$ = !"#!"##$!"#!"#$%#×(!!!"#) = !:!  !"#$%(!!!"#)   (20) 
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𝐸!!! = !:!  !"#$%(!!!"#) ×𝐸!  (21) 
 The relationship between 𝐸!!! and true Eh for drugs with B:P ratios of less than, equal to, 
or greater than 1 are shown in Figure (3).  Additionally, the relationship is also shown for a case 
when the drug does not penetrate into the red blood cells (RBC) at all (B:P ratio of 0.55, 
assuming a HCT value of 0.45). As demonstrated in Figure (3), except for the case of no RBC 
penetration, the value of 𝐸!!! is always an overestimation of the true Eh, regardless of the B:P 
ratio. However, as expected from Equation (21), the degree of overestimation increases linearly 
as the B:P value increases (Fig. 3).  Only when the drug does not enter RBC at all, are the values 
of 𝐸!!!and Eh identical (Fig. 3). This conclusion may also be made from the substitution of (1-
HCT) in place of B:P ratio in Equation (21) when the drug resides only in the plasma.  
 A comparison of Figs. (2) and (3) suggests that the use of 𝐸!!! is potentially associated 
with more error than 𝐸!! . This is because whereas 𝐸!!  is different from Eh by a factor equal to B:P 
ratio (Equation 15), the error in 𝐸!!! is magnified by an additional term [1/(1− 𝐻𝐶𝑇)] (Equation 
21).      
An Example 
Assume a drug was administered intravenously at a dose of 20 mg, and the plasma 
concentrations were used for calculation of AUC, which resulted in a values of 500 µg.h/L. 
Using the plasma concentrations, instead of blood concentrations, and assuming a liver blood 
flow of 90 L/h in a 70 kg subject and elimination by hepatic metabolism only, the 𝐸!!  of the drug 
is estimated to be 0.444 as demonstrated below: 
𝐶𝑙!,!"#$%# = 𝐷𝑜𝑠𝑒𝐴𝑈𝐶!"#$%# = 20,000  µμg500  µμg.h/L = 40.0  L/h 
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𝐸!! = 𝐶𝑙!,!"#$%#𝑄!,!"##$ = 40.0  L/h90  L/h = 0.444 
If instead of hepatic blood flow, hepatic plasma flow (49.5 L/h, assuming a hematocrit of 0.45) is 
used, the estimated 𝐸!!! is equal to 0.808: 
𝐸!!! = 𝐶𝑙!,!"#$%#𝑄!,!"#$%# = 40.0  L/h49.5  L/h = 0.808 
As it can be seen, the values of 𝐸!!! (0.808) and 𝐸!!  (0.444) are substantially different from each 
other. Now, if in reality the B:P ratio is equal to 1, 𝐸!!  would be the same as the true Eh of the 
drug (0.444) because blood and plasma clearances would be equal. Therefore, estimation of Eh 
from division of plasma Clh by hepatic blood flow is accurate if B:P is equal to 1. However, 𝐸!!! 
(0.808) gives an incorrect answer even when the B:P ratio is equal to 1. In this case, 𝐸!!! (0.808) 
would be higher than the true Eh (0.444) by factor of 1/(1− 𝐻𝐶𝑇)  or 1.82.  
Now, let us assume the B:P ratio is > 1, for example 1.5. In this case, the blood AUC 
(𝐴𝑈𝐶!"##$) and blood Clh will be as calculated below: 𝐴𝑈𝐶!"##$ = 𝐴𝑈𝐶!"#$%#×  𝐵:𝑃  𝑅𝑎𝑡𝑖𝑜 = 500  ×1.5 = 750  µμg.h/L 
𝐶𝑙!,!"##$ = 𝐷𝑜𝑠𝑒𝐴𝑈𝐶!"##$ = 20,000  µμg750  µμg.h/L = 26.7  L/h 
 Therefore, the true Eh will be 0.296: 
𝐸! = 26.7  L/h90  L/h = 0.296 
Consequently, the value of 𝐸!!  (0.444) would be an overestimation of the true Eh (0.296), by a 
factor equal to the B:P ratio or 1.5, when the B:P ratio is > 1. Additionally, 𝐸!!! (0.808) would be 
even more overestimated because it is higher than Eh (0.296) by a factor equal to (𝐵:𝑃  𝑅𝑎𝑡𝑖𝑜)/(1− 𝐻𝐶𝑇) or 2.73.  
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 If the B:P ratio is less than 1, for example 0.7,  the blood AUC (𝐴𝑈𝐶!"##$) would be 350 
µg.h/L (500 x 0.7), and the blood Clh would be 57.1 L/h (20,000/350), resulting in a true Eh of 
0.635: 
𝐸! = 57.1  L/h90  L/h = 0.635 
Therefore, 𝐸!!  (0.444) would be an underestimation of the true E (0.635), by a factor equal to B:P 
ratio (0.7), when the B:P ratio is < 1. Still, 𝐸!!! (0.808) would be an overestimation of the true 
value of Eh (0.635), by a factor of (𝐵:𝑃  𝑅𝑎𝑡𝑖𝑜)/((1− 𝐻𝐶𝑇) or 1.27, in the presence of B:P ratio 
of < 1. 
 Lastly, let us assume the extreme case when the drug does not penetrate into RBC at all. 
This is true for macromolecules such as dextrans [10] and some cell-impermeable small 
molecules, such as olmesartan [11]. In this case, the blood AUC would be equal to 275 µg.h/L 
and blood Clh would be equal to 72.7 L/h: 𝐴𝑈𝐶!"##$ = 1− 𝐻𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡 ×𝐴𝑈𝐶!"#$%# = 1− 0.45 ×500 = 275  µμg. h/L 
𝐶𝑙!,!"##$ = 𝐷𝑜𝑠𝑒𝐴𝑈𝐶!"##$ = 20,000  µμg275  µμg.h/L = 72.7  L/h 
Therefore, the true Eh would be 0.808: 
𝐸! = 72.7  L/h90  L/h = 0.808 
Therefore, the true Eh is identical to 𝐸!!! (0.808) when the drug does not enter RBC. However, as 
expected 𝐸!!  (0.444) is an underestimation of the true Eh (0.808) when B:P is less than 1, 
including this extreme case of low B:P ratio. 
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RECOMMENDATIONS 
It is suggested that in vivo Eh should be estimated using whole blood concentrations and 
liver blood flow [12], whenever possible. When whole blood samples are not available and 
plasma samples are analyzed, the plasma data should be converted to whole blood concentrations 
using a separately determined B:P ratio: 𝐴𝑈𝐶!"##$ = 𝐴𝑈𝐶!"#$%#×  𝐵:𝑃  𝑅𝑎𝑡𝑖𝑜 (22) 
Indeed, several investigators have correctly used this method for the estimation of Eh from the 
plasma data after correction for the B:P ratio [13-16]. One potential way to estimate the B:P ratio, 
in the absence of in vivo blood data, is by in vitro spiking of blank blood samples with the drug 
and measuring the total blood concentration and the resultant plasma concentrations [17]. If 
neither the blood concentration data nor B:P ratio is available, the use of 𝐸!!  (using plasma 
concentration and liver blood flow) might result in a reasonable estimate of true Eh because the 
B:P ratio of most drugs are close to 1. Otherwise, an overestimation or underestimation of the 
true value will result if the B:P ratio is >1 or < 1, respectively. The use of plasma clearance and 
plasma blood flow (𝐸!!!) should be avoided because it will always result in an overestimation of 
the true Eh, with potentially high errors, unless the drug does not penetrate the red blood cells.  
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LEGEND FOR FIGURES 
Fig. (1). Graphical representations of an eliminating organ. Cin and Cout represent concentration 
of the drug in the blood entering and leaving the organ, respectively, and Q represents the blood 
flow to the organ.  
Fig. (2). The relationship between hepatic extraction ratio obtained from the hepatic plasma 
clearance and liver blood flow (𝐸!! ) and true hepatic extraction ratio obtained from the hepatic 
blood clearance and liver blood flow for drugs with blood: plasma (B:P) ratios of 1.5, 1.0, and 
0.7. The slope of each line is equal to the corersponding B:P ratio. 
Fig. (3). The relationship between hepatic extraction ratio obtained from the hepatic plasma 
clearance and liver plasma flow (𝐸!!!) and true hepatic extraction ratio obtained from the hepatic 
blood clearance and liver blood flow for drugs with blood: plasma (B:P) ratios of 1.5, 1.0, 0.7, 
and 0.55. A hematocrit (HCT) value of 0.45 is assumed in generation of these lines. The slope of 
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